论文部分内容阅读
目的观察长春西汀联合依达拉奉治疗急性脑出血的临床效果。方法选择2010年6月—2012年6月收治的急性脑出血患者131例,随机分为观察组67例和对照组64例,两组均在常规治疗的基础上加用依达拉奉30 mg加生理盐水100 ml静脉滴注,2次/d。观察组在上述基础上加用长春西汀30 mg加生理盐水250 ml静脉滴注,1次/d。两组均治疗14 d。比较两组治疗后疗效、血肿量、神经功能缺损程度评分及格拉斯哥昏迷评分。计量资料采用u检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果总有效率观察组86.57%,对照组71.88%,观察组明显优于对照组,比较差异有统计学意义(χ2=4.318,P<0.05)。治疗后血肿量、神经功能缺损程度评分和格拉斯哥昏迷评分观察组[(8.62±4.29)ml、(12.36±3.78)分、(11.39±6.39)分]与对照组[(14.12±4.48)ml、(18.91±4.27)分、(18.53±5.92)分]比较差异均有统计学意义(u=7.171、9.280、6.638,均P<0.05)。结论长春西汀联合依达拉奉治疗急性脑出血效果明显,安全且无明显不良反应,值得推广。
Objective To observe the clinical effect of vinpocetine combined with edaravone in the treatment of acute cerebral hemorrhage. Methods 131 cases of acute cerebral hemorrhage admitted from June 2010 to June 2012 were randomly divided into observation group (67 cases) and control group (64 cases). Both groups were treated with edaravone 30 mg Plus saline 100 ml intravenously, 2 times / d. Observation group on the basis of the above plus vinpocetine 30 mg plus saline 250 ml intravenous infusion, 1 / d. Both groups were treated for 14 days. The curative effect, hematoma volume, neurological deficit score and Glasgow coma score of the two groups were compared. Measurement data using u test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate was 86.57% in the observation group and 71.88% in the control group, which was significantly better in the observation group than in the control group (χ2 = 4.318, P <0.05). After treatment, the scores of hematoma volume, neurological deficit score and Glasgow coma score in the observation group [(8.62 ± 4.29) ml, (12.36 ± 3.78), (11.39 ± 6.39) points vs control group [(14.12 ± 4.48) 18.91 ± 4.27), (18.53 ± 5.92) points respectively. There was significant difference between them (u = 7.171, 9.280, 6.638, all P <0.05). Conclusion Vinpocetine combined with edaravone in the treatment of acute cerebral hemorrhage was effective, safe and no obvious adverse reactions, it is worth promoting.